Designing for clinical adoption in liquid biopsy implementation

Promising diagnostic technologies often demonstrate strong analytical validity yet stall before reaching routine clinical care. The barrier is rarely technical performance alone; it is the absence of early alignment with clinical workflows, reimbursement pathways, and system-level feasibility.

I co-designed a translational framework that brought clinicians, laboratory scientists, health economists, industry, and payers into structured dialogue. The focus was to define minimum performance thresholds, clinical utility standards, workflow integration requirements, and early health economic modelling needed for real-world adoption.

The framework informed national policy discussions on how complex molecular diagnostics, including ctDNA assays, can transition from research environments into reimbursable clinical pathways.

Further reading:

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics (2021).